Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

NCT01622348 is registered in ClinicalTrials.gov with Idera Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01622348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01622348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
Lead sponsor
Idera Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
December 31, 2012
Enrollment
44 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

actively extending plaque psoriasis, moderate to severe plaque psoriasis